Ultrasound Guided Continuous Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Patients With Frozen Shoulder
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Zagazig University
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Visual analogue scale
Study Overview
Brief Summary
The patients will be randomly allocated into two equal groups (each 20 patients) using sealed opaque numbered envelopes:
Control Group (C Group) : Patients receive continuous US suprascapular nerve block only.
Gabapentin Group (G Group) : Patients receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.
Both groups compared as regard:
Visual Analogue Scale Range of passive and active movements Patients satisfaction complication related to block The total dose of diclofenac sodium
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 21 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Body mass index ≥ 18 Kg/m2 ≤ 30Kg/m2
- •ASA I, II or III.
- •Cooperative patients.
Exclusion Criteria
- •local infection at site of injection.
- •coagulopathy
- •previous history of mental disorders or chronic drug abuse (opioids, tranquilizers)
- •known hypersensitivity to any of the drugs used in the study.
Arms & Interventions
Control Group (C Group)
Patients will receive continuous US suprascapular nerve block only.
Intervention: Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine (Procedure)
Gabapentin Group (G Group)
Patients will receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time.
Intervention: Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine (Procedure)
Outcomes
Primary Outcomes
Visual analogue scale
Time Frame: 6 weeks
10cm line where zero means no pain and ten means worse imaginary pain
Secondary Outcomes
- Range of passive and active movements(6 weeks)
- Patients satisfaction(6 weeks)
Investigators
Amr Shaaban Elshafei
AMR SHAABAN ELSHAFEI
Zagazig University